Michelle Robertson: Yes. So, Rob, I mean, we don’t disclose our annual OpEx — or our quarterly OpEx, but I can tell you that about half of our spend is in — on the both the RUBY trial and the TDT trial. So, we don’t expect an enormous increase quarter-over-quarter. But as we do dose more patients, obviously, our R&D spend will go up, but not substantially. And our current, I’ll just say one more, our current cash runway supports our RUBY trials.
Operator: Our next question is from Greg Harrison with Bank of America.
Unidentified Analyst: This is Mary Keith on for Greg. Thanks for taking our questions. So, with 19 patients enrolled and plans for 20 to be dosed by year-end. Maybe how many sickle cell patients have been currently treated with EDIT-301, and maybe how could we expect to see this represented in the efficacy readout by the year-end update? Thank you.
Baisong Mei: So, we have 19 patients enrolled. And among those, as we just mentioned, 4 have been dosed, and we actually have — more patients have been completed pheresis, and have CD34 cells edited and ready to schedule dosing. And then, we have other patients who are in the process of pheresis. And so we are very confident that we will be able to dose 20 patients by year-end.
Operator: Our next question is from Luca Issi with RBC Capital Markets.
Luca Issi: Maybe on beta thalassemia, obviously most patients are in Southern Europe, so wondering if you could comment on what’s the plan to capture that market. And maybe how you’re thinking about some of the key lessons learned from the unsuccessful launch of bluebird bio there? And then, maybe on sickle cell disease, wondering if you can comment on pricing. Obviously, report suggests $1.9 million. So, wondering if that is actually aligned with your thinking. And then, maybe lastly on LCA10, any update on partner discussions there?
Gilmore O’Neill: Thanks very much, Luca. So obviously, beta thalassemia is a disease that dominates parts of the world, particularly Europe, Southeast Asia, South Asia, amongst others. From a point of view of our forward-looking, we are actually focusing our efforts on North America currently. We have shared in the past that from an upside point of view, we are looking — open to partnering, ideally targeting as a partner with a large global footprint who would actually collaborate certainly in sort of ex-U.S. development and commercialization. So that’s what I would say I can talk about when we look to your point about beta thalassemia outside North America. I will say that we are happy — very happy with the progress that we’re making with execution here within the United States and North America.
With regard to pricing, I think it’s very early days yet for us to be talking about pricing. This is something that we would be very happy to discuss when we’re actually closer to approval and launching, and we’ll look forward to future conversations around there. Obviously, we look to the market evolution over that time, but we’re going to talk about that closer to launch and approval. And then, finally, with regard to LCA10, we have — we really have a practice of not really going into details until we have a deal signed and executed.
Baisong Mei: And maybe just add one more point — sorry, just add one more point. As Gilmore mentioned about pricing, right? So certainly, we are very early stage, and we are happy to see the community is looking to the value of this gene editing therapy, and we are happy to see that the report recently in this space. So we — as Gilmore mentioned, this will be evolving, but we are pleased to see that — the entire community recognize the value of the medicine in this field.
Operator: Our next question is from Jay Olson with Oppenheimer.
